

New treatment approved for deadly blood cancer

August 17 2017

(HealthDay)—The U.S. Food and Drug Administration on Thursday approved the anti-cancer drug Besponsa (inotuzumab ozogamicin) to treat B-cell acute lymphoblastic leukemia (ALL).

B-cell ALL is a rapidly growing cancer that occurs when the bone marrow makes too many B-cell lymphocytes, a type of white blood cell. Almost 6,000 people in the United States are likely to be diagnosed with the disease this year, and more than 1,400 are projected to die from it, according to estimates from the U.S. National Cancer Institute.

"For adult patients with B-cell ALL whose cancer has not responded to initial [treatment](#) or has returned after treatment, life expectancy is typically low," Dr. Richard Pazdur, director of the FDA's Oncology Center of Excellence, said in an agency news release. "These patients have few treatments available and today's approval provides a new, targeted treatment option."

Besponsa was evaluated in clinical studies involving 326 people with relapsed or refractory B-cell ALL who had received one or two prior treatments with other medication. More than 35 percent of people evaluated achieved complete remission for about eight months after taking Besponsa, compared with about 17 percent of those who took a different chemotherapy drug.

Common side effects of Besponsa included low blood platelets, low white-blood-cell count, infection, anemia, fatigue and severe bleeding.

The drug's label includes a boxed warning of possible severe liver damage. Pregnant or breast-feeding women shouldn't take Besponsa, the FDA said.

Approval was granted to Pfizer, based in New York City.

More information: SOURCE: Aug. 17, 2017 press release, U.S. Food and Drug Administration

To learn more, visit the [FDA](#).

Copyright © 2017 [HealthDay](#). All rights reserved.

Citation: New treatment approved for deadly blood cancer (2017, August 17) retrieved 24 April 2024 from <https://medicalxpress.com/news/2017-08-treatment-deadly-blood-cancer.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.